Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk ...

A simple change to the chemotherapy regimen for people with Hodgkin lymphoma could reduce the long-term health impacts that ...

A simple change to the chemotherapy regimen for people with Hodgkin lymphoma could reduce the long-term health impacts that ...

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when ...

For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high risk for ...

The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a ...

Opens in a new tab or window SAN ANTONIO -- Women with larger, genomically high-risk breast cancers had significantly lower risk of distant metastasis with chemotherapy that included an anthracycline, ...

Paclitaxel-based and nab-paclitaxel-based chemotherapy produced similar 5-year outcomes in patients with high-risk, HR+, HER2- early breast cancer.

Blincyto combined with chemotherapy significantly improves 3-year DFS rates in pediatric standard-risk B-ALL patients ...

The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...

Amgen (AMGN) announced new data from a Phase 3 study demonstrating that adding BLINCYTO (blinatumomab) to chemotherapy significantly ...